Shilpa Medicare Limited has appointed Dr Vellaian Karuppiah as its Chief Operating Officer (COO) – Formulations, effective April 23, 2026. The appointment was approved by the company’s Nomination and Remuneration Committee and disclosed to stock exchanges in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
In his new role, Dr Karuppiah will serve as a Senior Managerial Personnel in a full-time capacity, leading the company’s formulations operations and driving strategic initiatives across the business.
Dr Karuppiah brings over 33 years of extensive experience across the pharmaceutical value chain. His expertise spans formulation and analytical R&D, regulatory affairs, manufacturing science and technology (MS&T), technology transfer, engineering and projects, quality systems, EHS/ESG, supply chain management, production planning and inventory control (PPIC) and end-to-end manufacturing operations.
Over the course of his career, he has held senior leadership and C-suite roles at several globally recognized pharmaceutical organizations, including Gland Pharma Limited, Strides Group, Dr. Reddy’s Laboratories, Actavis and Orchid Healthcare. His career reflects strong global exposure and cross-functional leadership, with a consistent track record of driving operational excellence, regulatory compliance and business transformation.
Most recently, he served as COO at Acme Group and Immacule Lifesciences, where he played a key role in enhancing manufacturing efficiency, strengthening supply chain resilience, improving quality systems and integrating R&D capabilities to support organizational growth.
Dr Karuppiah holds a postgraduate degree and a doctorate in pharmacy, along with executive management qualifications from leading institutions in India and abroad.
The company expects his appointment to significantly strengthen its formulations business, enhance operational efficiencies and support long-term sustainable growth through strategic leadership and execution excellence.
